Maddi Olmayan Varlıklar

Intangible assets are non-physical resources that add value to a business but cannot be touched or seen. Examples include patents, copyrights, trademarks, and proprietary software. Unlike tangible assets such as machinery, intangibles are often central to competitive advantage and long-term profitability, particularly in technology and pharmaceutical sectors where intellectual property drives firm value.

Intangible assets are recorded on the balance sheet only when purchased, not when developed internally. For example, if a company acquires a patent for $50,000, that cost is capitalized as an asset. Internally developed ideas, like homegrown software or brand equity, are typically excluded because they cannot be reliably measured and verified for financial reporting purposes.

Intangible assets with finite useful lives are amortized over their lifespan. If a patent is valid for ten years, the company spreads its cost evenly across those years using straight-line amortization. This approach mirrors depreciation for physical assets, ensuring the asset's value is systematically expensed as it provides economic benefit to the business.

Purchased intangible assets have verifiable costs and are recorded on the balance sheet. Internally developed intangible assets, such as proprietary software or brand recognition created by the company, are typically not recorded because their value cannot be reliably measured. This conservative accounting approach ensures only measurable, objective items appear in financial statements.

A company that purchases a patent for a special coffee brewing technology for $50,000 gains the exclusive right to use that technology in its products. Although the patent itself is not a physical object like the coffee machine, it is valuable and recorded as an intangible asset on the balance sheet. The patent's cost is then amortized over its valid period.

Intangible assets reveal a company's true economic value beyond physical infrastructure. In sectors like technology and pharmaceuticals, intellectual property such as patents and proprietary software may represent more value than tangible assets. Understanding intangible assets helps stakeholders assess competitive advantage and long-term profitability potential.

Common intangible assets include patents, copyrights, trademarks, brand recognition, and proprietary software. Patents grant exclusive rights to use specific technologies; copyrights protect creative works; trademarks protect brand identity; and proprietary software represents unique technological capabilities. Each provides distinct competitive advantages and economic value to the business.